Results 41 to 50 of about 1,647 (162)

Outpatient parenteral antimicrobial therapy in pediatrics: the role of antimicrobial stewardship

Antimicrobial Stewardship & Healthcare Epidemiology
This study characterized outpatient parenteral antimicrobial therapy (OPAT) orders and associated antimicrobial stewardship program (ASP) pharmacist recommendations made in a freestanding children’s hospital.
Daniel J. Trisno, Lauren Puckett, Alexandria Jensen, Hayden T. Schwenk   +3 more
doaj   +1 more source

Outpatient parenteral antimicrobial therapy for orthopedic infections – a successful public healthcare experience in Brazil

Brazilian Journal of Infectious Diseases, 2016
Treatment of orthopedic infections usually requires prolonged antimicrobial therapy, ranging from 14 days up to 6 months. Nowadays, rising levels of antimicrobial resistance demands parenteral therapy for many patients.
Priscila Rosalba Oliveira, Cassia da Silva Felix, Vladimir Cordeiro de Carvalho, Arlete Mazzini Giovani, Rosangela Suarti dos Reis, Marisa Beraldo, Edmir Peralta Albuquerque, Walter Cintra Ferreira, Junior, Jorge dos Santos Silva, Ana Lucia Lei Lima   +9 more
doaj   +1 more source

Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses

BMJ Open, 2021
Objectives To compare costs associated with different models of outpatient parenteral antimicrobial therapy (OPAT) delivery with costs of inpatient (IP) care across key infection groups managed via OPAT in the UK.Design A cost-minimisation design was ...
Mark Gilchrist, Maria Dimitrova, R A Seaton   +2 more
doaj   +1 more source

Delivery, setting and outcomes of paediatric Outpatient Parenteral Antimicrobial Therapy (OPAT): a scoping review [PDF]

BMJ Open, 2018
Background There has been little detailed systematic consideration of the delivery, setting and outcomes of paediatric Outpatient Parenteral Antimicrobial Therapy (OPAT), although individual studies report that it is a safe and effective treatment ...
Bernie Carter, Enitan D Carrol, David Porter, Matthew Peak, David Taylor-Robinson, Debra Fisher-Smith, Lucy Blake   +6 more
openaire   +3 more sources

An evaluation of risk factors for readmission in patients receiving outpatient parenteral antimicrobial therapy

Therapeutic Advances in Infectious Disease, 2023
Background: Outpatient parenteral antimicrobial therapy (OPAT), when required, is beneficial to patients and healthcare systems by reducing hospital length-of-stay, providing cost savings, and improving patient satisfaction.
Abby C. Bradley, Mary Joyce B. Wingler, Katherine L. Artman, Lori M. Ward, Jose Lucar   +4 more
doaj   +1 more source

Home‐Based Versus In‐Hospital Care in Pediatrics: A Systematic Review of Cost‐Effectiveness Studies

World Medical &Health Policy, Volume 18, Issue 2, June 2026.
ABSTRACT Home‐based care has emerged as a potential alternative to traditional hospital‐based care for children and adolescents worldwide. This systematic review aimed to systematically gather and critically assess the available evidence on the cost‐effectiveness of home‐based versus in‐hospital care for pediatric populations globally.
Luís Carlos Lopes‐Júnior, Raphael Manhães Pessanha, Wesley Rocha Grippa, Jonathan Grassi, Luiz Cláudio Barreto Silva Neto, Mariana Rabello Laignier, María Liliana Vásquez Ponce, Karla Anacleto de Vasconcelos, Regina Aparecida Garcia de Lima   +8 more
wiley   +1 more source

Healthcare utilization and outcomes of patients discharged to skilled nursing facilities on parenteral antimicrobial therapy

Antimicrobial Stewardship & Healthcare Epidemiology
Hospitalized patients are commonly discharged to skilled nursing facilities (SNFs) on outpatient parenteral antimicrobial therapy (OPAT). In this study, 101 patients discharged to a SNF on OPAT required considerable post-hospital care coordination and ...
Madeline Langenstroer, Christopher Crnich, Sally A. Jolles, Jon P. Furuno, Brie N. Noble, Rosemary C. Bailey   +5 more
doaj   +1 more source

Cost‐Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom

Mycoses, Volume 69, Issue 2, February 2026.
ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Noemi Muszbek, Alisha Angdembe, Carolina Garcia‐Vidal, Inga Bielicka, Keith R. Abrams, Keith Tolley, Markus Ruhnke, Maximilian Lebmeier, Neil Hawkins, Nick Manamley, Sara Dickerson   +10 more
wiley   +1 more source

Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States

Antimicrobial Stewardship & Healthcare Epidemiology, 2022
Objectives: To define outpatient parenteral antimicrobial therapy (OPAT) clinical pharmacy practice across the United States, specifically pharmacist functions, design of pharmacist involvement, and to compare pharmacist training of those who practice in
Christina G. Rivera, Kristin C. Mara, Monica V. Mahoney, Keenan L. Ryan   +3 more
doaj   +1 more source

Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real‐World Clinical Practice

Mycoses, Volume 69, Issue 2, February 2026.
ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Jorge Boán, Eduardo Aparicio‐Minguijón, Mario Fernández‐Ruiz, María Asunción Pérez‐Jacoiste Asín, Isabel Rodríguez‐Goncer, Francisco López‐Medrano, Rafael San‐Juan, José Tiago Silva, Ana Pérez‐Ayala, Jose Manuel Caro‐Teller, José María Aguado   +10 more
wiley   +1 more source